Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Mink Therapeutics Inc INKT

Healthcare Biotechnology
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:INKT)

MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update

GlobeNewswire 11 days ago

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

GlobeNewswire November 11, 2024

MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

GlobeNewswire November 7, 2024

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

GlobeNewswire October 31, 2024

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

GlobeNewswire October 8, 2024

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

GlobeNewswire October 4, 2024

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

GlobeNewswire September 3, 2024

MiNK Reports Second Quarter 2024 Results and Business Update

GlobeNewswire August 13, 2024

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

GlobeNewswire August 1, 2024
View More News ››

Opinion & Analysis (NDAQ:INKT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:INKT)

MiNK Therapeutics, Inc. (INKT): A Promising Biotech Poised f

http://beyondspx.com/2024/08/01/mink-therapeutics-inc-inkt-a-promising-biotech-poised-for-transformative-growth/
MikeTester - August 2, 2024

MiNK Therapeutics to Provide Corporate Update and Second Qua

Breaking News: $INKT MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial ReportNEW YORK, Aug. 01, 2024...
whytestocks - August 1, 2024

MiNK Therapeutics' AgenT-797 Shows Promising Results in the

Just In: $INKT MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published...
whytestocks - February 6, 2024
View more Bullboard ››

Cascadia Minerals Ltd

Cascadia Minerals Ltd

Cascadia is a Canadian junior mining company focused on exploring for copper and gold in the Yukon and British Columbia ...
View More »